Eurizon Capital SGR S.p.A. Takes $65.91 Million Position in Elevance Health, Inc. $ELV

Eurizon Capital SGR S.p.A. acquired a new stake in Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 188,081 shares of the company’s stock, valued at approximately $65,906,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ELV. Physician Wealth Advisors Inc. raised its holdings in Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the last quarter. Activest Wealth Management raised its holdings in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the last quarter. Rossby Financial LCC raised its holdings in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares during the last quarter. ORG Partners LLC raised its holdings in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after buying an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Elevance Health during the 4th quarter valued at $38,000. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Up 0.4%

Shares of Elevance Health stock opened at $394.40 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a 50-day moving average of $343.75 and a 200 day moving average of $338.90. The firm has a market cap of $85.65 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.22 and a beta of 0.66. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $408.00.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ELV. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Leerink Partners set a $364.00 price target on shares of Elevance Health in a report on Thursday, April 23rd. Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $405.00 to $435.00 in a report on Wednesday, April 29th. Barclays upped their price objective on shares of Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Guggenheim upped their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $403.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.